<DOC>
	<DOCNO>NCT00813800</DOCNO>
	<brief_summary>Patients bipolar disorder one high rate nicotine dependence one low quit rate . Varenicline show previous trial effective smoking cessation , studied subject bipolar disorder . This 12-week open label trial conduct assess feasibility , acceptability , safety varenicline bipolar depress smoker , give addition subject 's primary treatment bipolar disorder . The primary study hypothesis abstinence rate bipolar depress patient 50 % .</brief_summary>
	<brief_title>Varenicline Bipolar Depressed Patients</brief_title>
	<detailed_description>Varenicline , nicotinic acetylcholine receptor partial agonist , show two placebo-controlled trial efficacious smoke cessation . Given high prevalence nicotine dependence bipolar disorder high prevalence sub-syndromal syndromal depressive symptom bipolar disorder , 12-week adjunctive varenicline open label trial conduct assess feasibility , acceptability , safety varenicline bipolar depress smoker . All subject receive individual behavioral counseling . Primary hypothesis : abstinence rate bipolar depress patient 50 % . Secondary hypothesis : At final visit , bipolar depress patient achieve remission , define Montgomery Asberg Depression Rating Scale ( MADRS ) &lt; 8 , high rate tobacco abstinence depress patient achieve remission ( MADRS &gt; /= 8 ) .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Age 18 65 year Meet DSMIV criterion bipolar disorder type I II nicotine dependence DSMIV confirm current major depressive episode OR current depressive symptom define MADRS &gt; 4 &amp; &lt; 20 Smoke least 10 cigarette per day Fagerstr√∂m Test Nicotine Dependence ( FTND ) score 5 high Agree identify collateral individual contact purpose facilitate followup appointment Currently mood stabilization treatment . A minimum daily therapeutic dosage least one mood stabilizer , dose least 2 week : Lithium ( 0.61.2 mEq/L 900 mg ) , Valproate ( 50125 mg/mL 1000 mg ) , Carbamazepine ( 412 mg/mL 800 mg ) , Oxcarbazepine 1200 mg , Lamotrigine 100 mg , Olanzapine 10mg , Risperidone 2mg , Quetiapine 300mg , Ziprasidone 40mg , Aripiprazole 7.5 mg Antidepressants exclusionary . Topiramate acceptable mood stabilization treatment . There evidence base ( Delbello et al . 2005 ) highlight efficacy topiramate monotherapy acute mania child adolescent bipolar disorder type 1 . [ Mood stabilizer standard American Psychiatric Association ( APA ) treatment guideline Bipolar I disorder ( history mania ) . While guideline Bipolar II disorder unclear ( history hypomania ) , feel mood stabilization provide standardization treatment maximize safety ( ie : preventing switch depression mania hypomania ) . ] DSMIV dependence substance nicotine caffeine within past 3 month . DSMIV criterion schizophrenia nonaffective psychotic disorder Psychotic symptom within past month Active suicidality measure screening question ColumbiaSuicide Severity Rating Scale ( CSSRS History medically serious suicide attempt review doctor . Current use ( past 30 day ) smoke cessation treatment Pregnant nursing woman , woman refuse use adequate birth control Serious , active unstable medical condition Individuals , investigator opinion , unable comply study procedure Inability provide write informed consent English Allergic reaction varenicline Individuals dialysis history kidney disease ( varenicline excrete 96 % unchanged kidney ) Creatine supplementation current anticipated daily NSAID use Presence personality disorder , upon review medical record , appear primary reason psychiatric care .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Smoking</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Depression</keyword>
</DOC>